top of page
The Sound of Evolution
Ledipasvir
Mechanism of action:
Ledipasvir is a hepatitis C virus (HCV) NS5A inhibitor. NS5A is a multifunctional nonstructural protein involved in the formation of the viral RNA replication complex as well as viral particle assembly and maturation. After binding to NS5A, ledipasvir disrupts its normal function, thereby inhibiting both viral RNA replication and viral particle assembly.
Reference(s):
1. Kumari R et al. (2015). Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1. Expert Opin Pharmacother.
2. Younossi ZM et al. (2015). Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1, -2, and -3 clinical trials. Hepatology.
bottom of page